Matthew Sieben

Profil Matthew Sieben

Matthew is an associate in our Private Capital practice based in our New York office. He regularly advises private equity sponsors, venture capital funds and strategic clients on domestic and cross-border transactions, including mergers, acquisitions, investments, leveraged buy-outs, carve-outs and joint ventures.

Mandate

Private Equity

• H.I.G Capital on its acquisition of Mainlines Information Systems
• Apollo Global Management on its strategic partnership and financing of the physician-led buyout of GI Alliance, the nation's largest GI practice valued at $2.2 billion
• TPG on its:
  • investment in Palmetto Clean Technology
  • investment in K2 Medical Research
• A private equity firm on its investment in a clinical-stage biotech company advancing new therapies to treat inflammation
• A middle market private equity firm on its acquisitions of private companies from a media conglomerate
• A private equity sponsor on its acquisition of an infrastructure company
• A sovereign wealth fund on multiple venture capital investments in the life sciences and education industries

Going-Private Transactions

• Tenneco on its $7.1 billion sale to Apollo Global Management
• Stericycle on its proposed $7.2 billion sale to Waste Management

Carve-Out Transactions and Strategic M&A

• A financial learning platform for kids and parents on its acquisition of the talent, technology and IP of an alternative investing platform
• Crown Paper Group, a holding company for investments in the paper and packaging industries, in its acquisition by Atlas Holdings
• Multiple international corporations on international sanctions and the divestiture of Russian subsidiaries
• A luxury consumer goods company on its sale of a minority interest to a private equity sponsor

SPACs

• VPC Impact Acquisition Holdings on its investment in Bakkt Holdings, LLC.
• VPC Impact Acquisition Holdings II on its investment in FinAccel Pte. Ltd.
• VPC Impact Acquisition Holdings III, Inc. on its investment in Dave, Inc.
• CM Life Sciences II Inc. on its investment in SomaLogic, Inc.
• CM Life Sciences III Inc. on its investment in EQRx, Inc.